DEC 17, 2020 4:00 PM PST

Molecular Mechanism Behind Ketamine for Depression Discovered

WRITTEN BY: Annie Lennon

Over 30% of people with major depressive disorder are resistant to serotonin reuptake inhibitors (SSRI's), the current frontline prescription drug for the condition. Researchers are thus scrambling to find an alternative. Now, researchers from Canada have found that ketamine works against depression via a group of proteins involved in memory formation. Their discovery will go on to create better treatments for some patients with major depression. 

Ketamine was initially approved by the FDA as an anaesthetic in the 1970's. However, research has since found that it is also effective against depression. Unlike standard treatments for the condition, which typically take weeks to have an effect, ketamine works within hours. And now, researchers have uncovered one of the molecular mechanisms behind this effect. 

For their study, they examined the effects of ketamine on behavior and neuronal activity in mice. They used genetic tools to remove 4E-BP proteins (important for switching protein synthesis for memory formation on or off) from excitatory neurons (which make up most of the neurons in certain areas of the brain) and inhibitory neurons (those which control excitatory neurons) to see how ketamine worked in each case. 

In the end, the found that when 4E-BP proteins were absent from both types of neurons, ketamine was unable to relieve depressive behaviors and neuronal patterns. This came as these proteins were able to turn protein synthesis necessary for memory formation on or off. 

"Too many decisions continue to be made by a trial-and-error approach that can prolong the suffering of patients and affect their quality of life," says co-author of the study, Argel Aguilar-Valles. 

"Our discovery has the potential to bring us closer to find a safer alternative to ketamine, and ultimately to a personalized medicine approach, where medical treatments are tailored to the individual characteristics of each patient."

 

Sources: Neuroscience NewsNature

 

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 16, 2022
Drug Discovery & Development
The Age of mRNA Cancer Vaccines Starts with Melanoma
The Age of mRNA Cancer Vaccines Starts with Melanoma
Earlier this week, pharmaceuticals Merck and Moderna announced “the first demonstration of efficacy” for an ...
JAN 05, 2023
Cancer
A Triple Immunotherapy Regimen for Pancreatic Cancer
A Triple Immunotherapy Regimen for Pancreatic Cancer
Immunotherapy, including immune checkpoint inhibitors (ICIs), has changed the landscape of cancer treatment in the last ...
JAN 13, 2023
Drug Discovery & Development
Developing the First and Only Peptide-Formulated Neuromodulator for Wrinkles
Developing the First and Only Peptide-Formulated Neuromodulator for Wrinkles
In a wrinkle-reduction market run by AbbVie’s Botox™ (active ingredient onabotulinumtoxinA), Revance was jus ...
JAN 19, 2023
Immunology
Surprising Finding Opens Up Novel Treatment Avenues for Lupus
Surprising Finding Opens Up Novel Treatment Avenues for Lupus
Lupus is an autoimmune disease that causes pain, inflammation and tissue damage. It can affect the brain, skin, joints, ...
JAN 23, 2023
Drug Discovery & Development
New protein discovery holds promise for developing more effective snake anti-venoms
New protein discovery holds promise for developing more effective snake anti-venoms
Venomous snakes, which include cobras, vipers, and rattlesnakes, can pose a significant danger to humans. In the Un ...
JAN 28, 2023
Drug Discovery & Development
Parkinson's Drug May Reduce Brain Inflammation from Depression
Parkinson's Drug May Reduce Brain Inflammation from Depression
Levodopa, a drug used to increase dopamine levels in people with Parkinson’s disease, may also reverse the effects ...
Loading Comments...